THALES
8.10.2020 09:02:14 CEST | Business Wire | Press release
Thales today announced a new high-performance data security solution for Teradata customers using the Vantage platform for data and analytics. By providing users with a totally transparent and scalable encryption solution to protect data at rest in any environment, the Thales Transparent Encryption solutions enable Teradata Vantage customers to better meet compliance and privacy regulations through encryption, access controls and data access audit logging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005043/en/
Easily deployed across files and systems, this solution enables data at rest to be quickly encrypted within the Vantage platform. Since it is “transparent”, it is simple to deploy because there are no application development or database integration changes required. The cost-effective solution removes data breach risks and supports compliance initiatives while saving organisations months on the deployment of data protection for a Teradata environment.
Effective Access Policy Management at Scale
Thales’ Transparent Encryption is completely invisible to Vantage users and administrators as long as they are authorised to access the databases and system files they won’t know that solution is protecting your business. However, processes and actions from unauthorised users are immediately stopped and logged. The solution can be flexibly deployed across physical, virtual and cloud environments, giving organisations the ability to implement granular access policies that allow administrators to access infrastructure and systems without ever being able to see sensitive data in clear text.
The solution is designed to meet the high-scale and performance requirements of Vantage deployments on-premises, in clouds and hybrid, which can be several hundred terabytes to many petabytes in size and contain highly sensitive and regulated data and subsequently subject to privacy regulations (e.g., GDPR, CCPA, etc.). The scalable solution provides little overhead, from encryption and decryption activities, letting users robustly secure data and retain critical I/O and storage efficiencies.
“We’re pleased to have worked with the Teradata team to expand the Thales offering to include the transparent encryption solutions for Teradata. Our existing joint customers will simply expand their data security platform investment to include their Vantage environment. They will find that the policies for encryption, privileged user access and the additional security intelligence logs to further enhance their visibility are entirely familiar. New customers will be taking their first steps in unifying all their data security requirements and use cases on one easy to use, scalable and high-performance platform. The Thales solution complements the rich set of controls in the Vantage environment, ensuring that deployments meet the toughest regulatory audit scrutiny and protects a company’s most valuable data,” said Todd Moore, Senior Vice President, Encryption Solutions at Thales .
Jay Irwin JD, Director of Teradata Center for Enterprise Security added: "Teradata’s customer base is comprised of some of the largest and most data-centric companies on the planet. Security at scale is vital to this clientele, which makes Thales’ solution a particularly good fit for enabling Teradata's best-in-industry cloud security to be even more robust. With the application of Thales transparent encryption solutions, we provide a layered defense that protects customer data on-premises, in the cloud and in hybrid environments – all deployment types that our customers use today.”
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
